SVA
What one share of Sinovac Biotech holds
Pharmaceutical Preparations
We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs.
Sinovac Biotech’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $5.37 |
|---|---|
| Profit | −$0.83 |
| Capex (buildings and equipment) | $0.68 |
| Free cash flow | −$7.81 |
| Dividends | $55.00 |
| Cash and investments | $6.79 |
| Debt | $6.89 |
| Book value | $61.77 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.27 | −$0.01 | $0.22 | −$0.47 | — | $2.03 |
| 2017 | $3.05 | $0.45 | $0.21 | $0.84 | — | $2.64 |
| 2018 | $3.53 | $0.34 | $0.09 | $0.04 | — | $3.56 |
| 2019 | $2.24 | $0.41 | $0.10 | $0.26 | — | $2.97 |
| 2020 | $4.49 | $0.97 | $1.12 | $3.10 | — | $7.52 |
| 2021 | $270.47 | $113.44 | $8.30 | $205.70 | — | $125.41 |
| 2022 | $20.53 | $0.20 | $4.37 | −$15.49 | — | $118.38 |
| 2023 | $6.54 | −$0.19 | $2.17 | −$0.24 | — | $115.72 |
| 2024 | $5.03 | $1.26 | $1.34 | −$2.13 | — | $114.98 |
| 2025 | $5.37 | −$0.83 | $0.68 | −$7.81 | $55.00 | $61.77 |